Clinical trials
Postoperative Complications trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 2 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 4 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 1 |
| 2018 | 7 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 8 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 45 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The Second Affiliated Hospital of Chongqing Medical University | 3 |
| Xijing Hospital | 3 |
| Chinese PLA General Hospital | 2 |
| First Affiliated Hospital of Chongqing Medical University | 2 |
| Shanghai Minimally Invasive Surgery Center | 2 |
| Air Force Military Medical University, China | 1 |
| Beijing Chao Yang Hospital | 1 |
| Beijing Tiantan Hospital | 1 |
| Beijing Tsinghua Chang Gung Hospital | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Postoperative Complications | 45 |
| Rectal Neoplasms | 3 |
| Cardiomyopathy, Hypertrophic | 2 |
| Delirium | 2 |
| Emergence Delirium | 2 |
| Recurrence | 2 |
| Acute Kidney Injury | 1 |
| Breast Neoplasms | 1 |
| COVID-19 | 1 |
| Cardiovascular Diseases | 1 |
Trials
Showing 1 to 25 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.